Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
While the president temporarily shores up leadership at the OSTP, the NIH is losing another long-time career researcher, John R. Mascola.
95% of those surveyed agreed that the pandemic showed the vulnerabilities of the medicine supply chain.
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
On Wednesday, Third Harmonic Bio closed on Series B financing, bringing the total capital raised to $155 million.
Star Therapeutics has exited stealth mode and announced a spin-off company, Electra Therapeutics.
Moderna announced plans to expand in Asia with the opening of four new subsidiaries in Malaysia, Taiwan, Singapore and Hong Kong.
HOOKIPA Pharma Inc.’s shares have soared after stating it amended and restated a collaboration and license agreement with Gilead Sciences to develop immunotherapies against HIV.
TenSixteen Bio recently came out of stealth mode with $40 million in funding to target somatic mosaicism – particularly clonal hematopoiesis of indeterminate potential (CHIP).
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.